Nelfinavir
- Generic Name
- Nelfinavir
- Brand Names
- Viracept
- Drug Type
- Small Molecule
- Chemical Formula
- C32H45N3O4S
- CAS Number
- 159989-64-7
- Unique Ingredient Identifier
- HO3OGH5D7I
- Background
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2005-08-01
- Target Recruit Count
- 115
- Registration Number
- NCT00122590
- Locations
- 🇫🇷
Service de Medecine Interne Hopital Cochin, Paris, France
TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 20
- Registration Number
- NCT00023400
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.